Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZIM2 antisense RNA 1 (ZIM2-AS1, or ZIM2as) is a primate-specific long non-coding RNA transcribed antisense to the ZIM2 gene (zinc finger imprinted gene 2), a member of the imprinted PEG3 domain locus. ZIM2-AS1 was identified in human brain and testis, with expression also observed in other primates like chimpanzee and orangutan[1]. It does not appear to encode protein. ZIM2-AS1 is involved in regulating the local epigenetic environment, as suggested by its association with allele-specific DNA methylation patterns near its promoter and in adjacent regulatory regions. While the biological functions of ZIM2-AS1 remain to be fully characterized, by analogy to other antisense lncRNAs, it may participate in the fine-tuning of imprinted gene expression, possibly through chromatin remodeling, recruitment of regulatory proteins, or interference with transcription[1][2]. No direct therapeutic targeting or disease association is currently reported for ZIM2-AS1, and it is not established as a druggable therapeutic target. Key notes: - ZIM2-AS1 is not a protein, enzyme, transporter, or receptor, but rather a non-coding regulatory RNA. It is not recognized as a therapeutic target in current biomedical practice[1]. - The information on specific biological or disease roles is inferred from general properties of long non-coding antisense RNAs, as disease-specific roles for ZIM2-AS1 are not established in the literature[1][2]. - No known drugs, mechanisms of action, biomarkers, or safety concerns are associated with this target at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZIM2 antisense RNA 1 (ZIM2-AS1).